Valuation : Fortress Biotech, Inc.

Market Cap 91.21M 78.68M 74.01M 67.43M 127M 8.66B 127M 875M 341M 4.4B 342M 335M 14.6B P/E 2026 *
1.07x
P/E 2027 * -2.74x
Enterprise Value 91.21M 78.68M 74.01M 67.43M 127M 8.66B 127M 875M 341M 4.4B 342M 335M 14.6B EV / Sales 2026 *
1.16x
EV / Sales 2027 * 0.81x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 week-2.83%
Current month+0.55%
1 month-0.36%
3 months+7.00%
6 months-16.67%
Current year-24.86%
1 week 2.63
Extreme 2.63
2.88
1 month 2.57
Extreme 2.57
3.06
Current year 2.18
Extreme 2.18
4.53
1 year 2.18
Extreme 2.18
4.53
3 years 1.24
Extreme 1.24
6.15
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap. Importance
1/4/26 Free

Chief Financial Officer

2,967 0.0096%
18/3/26 Free

Chief Executive Officer

475,424 1.5318%
18/3/26 Free

Director

475,424 1.5318%
Change 5-day change 1-year change 3-year change Capi.($)
+0.18%-2.83%-7.72%-54.02% 91.21M
+1.89%-2.41%+40.76%-2.18% 79.79B
+0.43%+1.89%-19.06%-37.01% 58.85B
+6.07%-6.26%+515.48%+32.27% 56.03B
+0.13%-3.37%-1.24%+34.14% 51.26B
+1.49%-2.50%+9.69%+163.06% 47.68B
-0.27%-2.08%+54.82%-19.09% 32.01B
+0.32%-4.74%+43.72%+91.02% 24.98B
-2.12%+2.11%+4.90%+189.46% 23.05B
+1.69%-2.60%+61.63%+116.78% 16.31B
Average +0.97%-1.56%+70.30%+51.44% 39B
Weighted average by Cap. +1.47%-1.51%+90.70%+43.35%

Financials

2026 *2027 *
Net sales 78.79M 67.97M 63.93M 58.25M 110M 7.48B 110M 756M 294M 3.8B 296M 289M 12.61B 113M 97.69M 91.89M 83.72M 157M 10.75B 158M 1.09B 423M 5.47B 425M 416M 18.13B
Net income 88.25M 76.12M 71.6M 65.23M 123M 8.38B 123M 847M 329M 4.26B 331M 324M 14.13B -37.81M -32.62M -30.68M -27.95M -52.56M -3.59B -52.85M -363M -141M -1.83B -142M -139M -6.05B
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
02/09/26 USD 2.750 +0.55% 244,803
31/08/26 USD 2.735 -1.26% 326,337
28/08/26 USD 2.770 -1.07% 309,687
27/08/26 USD 2.800 -0.36% 463,476
26/08/26 USD 2.810 -0.71% 395,827
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.735USD
Average target price
11.00USD
Spread / Average Target
+302.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock